AV
Therapeutic Areas
CSL Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CSL312 (Garadacimab) | Hereditary Angioedema (HAE) Prophylaxis | Filed |
| CSL324 | Severe COVID-19 | Phase 3 |
| CSL889 (Etranacogene Dezaparvovec) | Hemophilia B | Phase 3 |
| Next-gen IgG Pipeline | Immunodeficiencies, Autoimmune Disorders | Phase 1-3 |
| Vifor Pipeline Assets | Kidney Disease, Iron Deficiency | Various |
| Seqirus mRNA/Cell-based Vaccines | Influenza | Research to Phase 3 |
Leadership Team at CSL
GN
Gordon Naylor
Chief Executive Officer and Managing Director
KL
Ken Lim
Chief Financial Officer
BM
Bill Mezzanotte
EVP, Head of R&D and Chief Medical Officer
MO
Mary Oates
EVP and Chief Operating Officer
AS
Andy Schmeltz
Chief Commercial Officer
SM
Steve Marlow
General Manager, CSL Plasma
DR
Dave Ross
SVP and GM, CSL Seqirus
HG
Hervé Gisserot
EVP, Business Development & Enterprise Alliance Management
MH
Mark Hill
Chief Digital Information Officer
DB
Dr. Brian McNamee
Board Chair